BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

January 7, 2013 8:00 AM UTC

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) was off $0.80 to $24.91 Christmas week after FDA approved Juxtapid lomitapide to treat patients with homozygous familial hypercholesterolemia (hoFH). Juxtapid was approved with a REMS and a boxed warning for hepatotoxicity. The drug is also under review for the indication in Europe, with a decision expected in mid-2013.

Depomed Inc. (NASDAQ:DEPO) gained $0.37 to $6.38 last week after FDA's Advisory Committee for Reproductive Health Drugs said it will meet on March 4 to discuss an NDA for Serada gabapentin to treat moderate to severe vasomotor symptoms associated with menopause (hot flashes). Serada has a May 31 PDUFA date...